Fuji Pharma Co Ltd banner

Fuji Pharma Co Ltd
F:FUP

Watchlist Manager
Fuji Pharma Co Ltd Logo
Fuji Pharma Co Ltd
F:FUP
Watchlist
Price: 9.5 EUR
Market Cap: €231m

Fuji Pharma Co Ltd
Investor Relations

Fuji Pharma is a Japanese pharmaceutical company that makes prescription medicines, with a strong focus on women’s health, especially drugs used in obstetrics and gynecology. It also sells contrast agents for medical imaging and other hospital medicines. Its products are used by doctors, hospitals, and clinics, not sold directly to consumers. The company earns money mainly by developing, manufacturing, and selling medicines to healthcare providers and drug wholesalers. It also supplies some generic and specialty products, which helps it serve both the hospital market and the wider prescription-drug market. Like most drug makers, it depends on product approvals, manufacturing quality, and relationships with medical institutions and distributors. What makes Fuji Pharma’s business different is its narrow focus on therapeutic areas that are often underserved, especially women’s health. That gives it a clear place in the healthcare supply chain: it is not a broad consumer health company, but a specialized maker of prescription products that hospitals and doctors rely on for specific treatments.

Show more
Loading...
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Mr. Toyoyuki Kamide
VP, Executive Officer & Director
No Bio Available
Mr. Seiichi Inoue
Managing Executive Officer & GM of Corporate Division
No Bio Available
Takeshi Sato
Managing Executive Officer
No Bio Available
Atsushi Mitsuhashi
Managing Executive Officer & SCM Manager
No Bio Available

Contacts

Address
TOKYO-TO
Chiyoda-ku
6F, Seito Kaikan, 5-7, Samban-cho
Contacts
+81335563344.0
www.fujipharma.jp
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett